Product Description
Fenfluramine is an amphetamine derivative and a sympathomimetic stimulant with appetite-suppressant property. Fenfluramine, which was part of the Fen-Phen anti-obesity medication, stimulates the release of serotonin from vesicular storage, and modulates serotonin transporter function. Since serotonin regulates mood and appetite, among other functions, increased serotonin level results in a feeling of fullness and loss of appetite. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Fenfluramine)
Mechanisms of Action: 5-HT Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Belgium | Canada | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Latvia | Lithuania | Netherlands | New Zealand | Pakistan | Peru | Poland | Portugal | Romania | Slovakia | Slovenia | Spain | Sweden | Taiwan | United Kingdom | United States | Uruguay | Venezuela
Approved Indications: Lennox Gastaut Syndrome | Seizures
Known Adverse Events: Lennox Gastaut Syndrome | Status Epilepticus | Lethargy | Respiratory Tract Infections | Asthenia | Constipation | Diarrhea
Company: UCB
Company Location: SMYRNA GA 30080
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Belgium, Canada, Denmark, France, Georgia, Germany, Ireland, Israel, Italy, Japan, Korea, Mexico, Netherlands, Norway, Poland, Portugal, Spain, Sweden, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 13
Highest Development Phases
Phase 3: Brain Diseases|CDKL5-deficiency Disorder|Dravet Syndrome|Epilepsies, Myoclonic|Epileptic Encephalopathy|Lennox Gastaut Syndrome
Phase 2: Epilepsy
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| EP0213 | P3 |
Unknown Status |
Dravet Syndrome |
2026-11-15 |
|
| ORCHID | P3 |
Recruiting |
Epilepsies, Myoclonic|Dravet Syndrome |
2026-10-30 |
|
| ZX008-2103/EP0216 | P3 |
Unknown Status |
CDKL5-deficiency Disorder |
2026-09-11 |
|
| jRCT2041230015 | P3 |
Recruiting |
CDKL5-deficiency Disorder |
2026-05-31 |